Genetic Technologies Stock Z Score
| GENE Stock | USD 2.37 0.05 2.16% |
Genetic | Z Score |
Genetic Technologies Company Z Score Analysis
Genetic Technologies' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Genetic Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Genetic Technologies is extremely important. It helps to project a fair market value of Genetic Stock properly, considering its historical fundamentals such as Z Score. Since Genetic Technologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Genetic Technologies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Genetic Technologies' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
According to the company's disclosures, Genetic Technologies has a Z Score of 0.0. This is 100.0% lower than that of the Life Sciences Tools & Services sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Genetic Technologies Current Valuation Drivers
We derive many important indicators used in calculating different scores of Genetic Technologies from analyzing Genetic Technologies' financial statements. These drivers represent accounts that assess Genetic Technologies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Genetic Technologies' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 685.0M | 2.4B | 784.4M | 636.2M | 731.6M | 628.9M | |
| Enterprise Value | 671.3M | 2.4B | 773.3M | 628.9M | 723.2M | 606.2M |
Genetic Technologies Institutional Holders
Institutional Holdings refers to the ownership stake in Genetic Technologies that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Genetic Technologies' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Genetic Technologies' value.| Shares | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 17.3 K | Rhumbline Advisers | 2023-12-31 | 3.7 K | Ubs Group Ag | 2023-12-31 | 3 K | Wells Fargo & Co | 2023-12-31 | 130 | Simplex Trading, Llc | 2023-12-31 | 18.0 | Scarborough Advisors, Llc | 2023-12-31 | 0.0 | Gradient Investments | 2023-09-30 | 0.0 | Virtu Financial Llc | 2023-09-30 | 0.0 | Newsquare Capital, Llc | 2023-09-30 | 0.0 | Two Sigma Securities, Llc | 2023-12-31 | 0.0 | Davis Capital Management | 2023-12-31 | 0.0 |
Genetic Fundamentals
| Return On Equity | -1.6 | ||||
| Return On Asset | -0.53 | ||||
| Profit Margin | (1.24) % | ||||
| Operating Margin | (1.06) % | ||||
| Current Valuation | 264.42 M | ||||
| Shares Outstanding | 3.85 M | ||||
| Shares Owned By Institutions | 0.64 % | ||||
| Number Of Shares Shorted | 11.53 K | ||||
| Price To Earning | (1.87) X | ||||
| Price To Book | 4.08 X | ||||
| Price To Sales | 1.29 X | ||||
| Revenue | 8.69 M | ||||
| Gross Profit | 6.01 M | ||||
| EBITDA | (9.24 M) | ||||
| Net Income | (11.75 M) | ||||
| Cash And Equivalents | 11.74 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 532.85 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 3.86 X | ||||
| Book Value Per Share | 0.04 X | ||||
| Cash Flow From Operations | (9.93 M) | ||||
| Short Ratio | 0.27 X | ||||
| Earnings Per Share | (0.15) X | ||||
| Target Price | 12.5 | ||||
| Number Of Employees | 60 | ||||
| Beta | 0.37 | ||||
| Market Capitalization | 10.38 M | ||||
| Total Asset | 14.86 M | ||||
| Retained Earnings | (156.72 M) | ||||
| Working Capital | 7.19 M | ||||
| Current Asset | 9.03 M | ||||
| Current Liabilities | 992 K | ||||
| Net Asset | 14.86 M |
About Genetic Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genetic Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genetic Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genetic Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Genetic Technologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Genetic Technologies' short interest history, or implied volatility extrapolated from Genetic Technologies options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Genetic Technologies Piotroski F Score and Genetic Technologies Valuation analysis. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Genetic Stock analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Genetic Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 2.73 | Quarterly Revenue Growth (0.02) | Return On Assets (0.53) | Return On Equity (1.60) |
The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.